Hosseinzadeh Fahimeh, Oskouei Nader Jangi, Ghavamzadeh Saeid
Department of Nutrition, Student Research Committee, Urmia University of Medical Sciences, Urmia 57147-83734, Iran.
Urmia University of Medical Sciences, Urmia 57147-83734, Iran.
Clin Nutr Res. 2020 Jan 23;9(1):20-31. doi: 10.7762/cnr.2020.9.1.20. eCollection 2020 Jan.
The receptor of vitamin D is expressed in almost all body cells, including vascular endothelial cells and cardiomyocytes. Vitamin D deficiency has been observed widespread amongst heart failure (HF) patients, which could have harmful effects on their health condition. This study aims to investigate the effect of vitamin D supplements on blood pressure (BP) and physical activity of HF patients. Thirty-nine systolic HF patients with low ejection fraction (EF) < 50% and class III of New York Heart Association functional classification were randomly divided into 2 groups including intervention and placebo to enroll in an 8 weeks double-blind clinical trial. During the trial 6-minute walk test (6MWT), 25-hydroxyvitamin D (25[OH]D) level, BP, sodium and potassium intakes were assessed. The mean 25(OH)D level increased to 28.9 ± 11.7 ng/mL (p < 0.001) in the intervention group. There was a poor but non-significant reduction in systolic BP (-0.033 ± 4.71 mmHg, p = 0.531) in the intervention group. The BP also did not change in the placebo group at the end of the trial. A negligible decrease of 6MWT was observed in the intervention group (-6.6 ± 29.2 m) compared to the placebo (-14.1 ± 40.5 m). However, differences between the 2 groups were not statistically significant (p = 0.325). The results solely showed a slight positive correlation between 25(OH)D level and 6MWT. No significant improvements in BP and 6MWT were observed after vitamin D3 supplementation.
Iranian Registry of Clinical Trials Identifier: IRCT2016102113678N13.
维生素D受体几乎在身体所有细胞中都有表达，包括血管内皮细胞和心肌细胞。心力衰竭（HF）患者中普遍存在维生素D缺乏的情况，这可能对他们的健康状况产生有害影响。本研究旨在探讨补充维生素D对HF患者血压（BP）和身体活动的影响。39名射血分数（EF）<50%且纽约心脏协会功能分级为III级的收缩性HF患者被随机分为两组，包括干预组和安慰剂组，参加一项为期8周的双盲临床试验。在试验期间，评估了6分钟步行试验（6MWT）、25-羟基维生素D（25[OH]D）水平、血压、钠和钾摄入量。干预组的平均25(OH)D水平升至28.9±11.7 ng/mL（p<0.001）。干预组的收缩压有轻微但不显著的降低（-0.033±4.71 mmHg，p=0.531）。试验结束时，安慰剂组的血压也没有变化。与安慰剂组（-14.1±40.5 m）相比，干预组的6MWT有可忽略不计的下降（-6.6±29.2 m）。然而，两组之间的差异无统计学意义（p=0.325）。结果仅显示25(OH)D水平与6MWT之间有轻微的正相关。补充维生素D3后，血压和6MWT没有显著改善。
伊朗临床试验注册中心标识符：IRCT2016102113678N13。
